Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | F7 | P08709 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855070 | 0.87 | PPID (0.46) | HDAC1HDAC2F7CA12CA1 | |
| SCHEMBL13855391 | 0.82 | HDAC1 (0.44) | HDAC1HDAC2F7F2CA12 | |
| SCHEMBL13855068 | 0.82 | F7 (0.47) | HDAC1HDAC2F7F2F10 | |
| SCHEMBL13855054 | 0.81 | SMN1; SMN2 (0.43) | ALDH1A1 | |
| SCHEMBL8899089 | 0.77 | F7 (0.40) | HDAC1HDAC2F7F2CA12 | |
| SCHEMBL10458385 | 0.76 | CA12 (0.50) | HDAC1HDAC2F7F2CA12 | |
| SCHEMBL13855055 | 0.75 | SMN1; SMN2 (0.42) | ALDH1A1MAPKAPK2 | |
| SCHEMBL8898242 | 0.75 | F7 (0.45) | HDAC1F7F2CA12CA1 | |
| SCHEMBL4413240 | 0.74 | F7 (0.44) | HDAC1F7F2CA12CA1 | |
| SCHEMBL8870526 | 0.73 | GAA (0.48) | CA12CA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISH HEALTHCARE AG (CH) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130085-A1 | Amidino-Compounds for Stabilizing Factor VII Polypeptide Formulations | F7, F5, F8 | HDAC1 3155/4885HDAC2 4308/4885F7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.